454 related articles for article (PubMed ID: 35377393)
1. Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients: A Randomized Clinical Trial.
Singh AK; Cizman B; Carroll K; McMurray JJV; Perkovic V; Jha V; Johansen KL; Lopes RD; Macdougall IC; Obrador GT; Waikar SS; Wanner C; Wheeler DC; Wiecek A; Stankus N; Strutz F; Blackorby A; Cobitz AR; Meadowcroft AM; Paul G; Ranganathan P; Sedani S; Solomon S
JAMA Intern Med; 2022 Jun; 182(6):592-602. PubMed ID: 35377393
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Daprodustat Compared with Darbepoetin Alfa in Japanese Hemodialysis Patients with Anemia: A Randomized, Double-Blind, Phase 3 Trial.
Akizawa T; Nangaku M; Yonekawa T; Okuda N; Kawamatsu S; Onoue T; Endo Y; Hara K; Cobitz AR
Clin J Am Soc Nephrol; 2020 Aug; 15(8):1155-1165. PubMed ID: 32723804
[TBL] [Abstract][Full Text] [Related]
3. Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis.
Singh AK; Carroll K; Perkovic V; Solomon S; Jha V; Johansen KL; Lopes RD; Macdougall IC; Obrador GT; Waikar SS; Wanner C; Wheeler DC; Więcek A; Blackorby A; Cizman B; Cobitz AR; Davies R; Dole J; Kler L; Meadowcroft AM; Zhu X; McMurray JJV;
N Engl J Med; 2021 Dec; 385(25):2325-2335. PubMed ID: 34739194
[TBL] [Abstract][Full Text] [Related]
4. Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis.
Singh AK; Carroll K; McMurray JJV; Solomon S; Jha V; Johansen KL; Lopes RD; Macdougall IC; Obrador GT; Waikar SS; Wanner C; Wheeler DC; Więcek A; Blackorby A; Cizman B; Cobitz AR; Davies R; DiMino TL; Kler L; Meadowcroft AM; Taft L; Perkovic V;
N Engl J Med; 2021 Dec; 385(25):2313-2324. PubMed ID: 34739196
[TBL] [Abstract][Full Text] [Related]
5. Three Times Weekly Dosing of Daprodustat versus Conventional Epoetin for Treatment of Anemia in Hemodialysis Patients: ASCEND-TD: A Phase 3 Randomized, Double-Blind, Noninferiority Trial.
Coyne DW; Singh AK; Lopes RD; Bailey CK; DiMino TL; Huang C; Connaire J; Rastogi A; Kim SG; Orias M; Shah S; Patel V; Cobitz AR; Wanner C
Clin J Am Soc Nephrol; 2022 Sep; 17(9):1325-1336. PubMed ID: 35918106
[TBL] [Abstract][Full Text] [Related]
6. Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis.
Eckardt KU; Agarwal R; Aswad A; Awad A; Block GA; Bacci MR; Farag YMK; Fishbane S; Hubert H; Jardine A; Khawaja Z; Koury MJ; Maroni BJ; Matsushita K; McCullough PA; Lewis EF; Luo W; Parfrey PS; Pergola P; Sarnak MJ; Spinowitz B; Tumlin J; Vargo DL; Walters KA; Winkelmayer WC; Wittes J; Zwiech R; Chertow GM
N Engl J Med; 2021 Apr; 384(17):1601-1612. PubMed ID: 33913638
[TBL] [Abstract][Full Text] [Related]
7. Phase 3, Randomized, Double-Blind, Active-Comparator (Darbepoetin Alfa) Study of Oral Roxadustat in CKD Patients with Anemia on Hemodialysis in Japan.
Akizawa T; Iwasaki M; Yamaguchi Y; Majikawa Y; Reusch M
J Am Soc Nephrol; 2020 Jul; 31(7):1628-1639. PubMed ID: 32493693
[TBL] [Abstract][Full Text] [Related]
8. Subcutaneous C.E.R.A. for the Maintenance Treatment of Anemia in Pediatric Patients With CKD: A Phase 2, Open-Label, Single-Arm, Multicenter Study.
Warady BA; Meyer Reigner S; Tirodkar C; Drozdz D
Am J Kidney Dis; 2023 Jun; 81(6):684-694.e1. PubMed ID: 36587890
[TBL] [Abstract][Full Text] [Related]
9. Study design and baseline characteristics of patients on dialysis in the ASCEND-D trial.
Singh AK; Blackorby A; Cizman B; Carroll K; Cobitz AR; Davies R; Jha V; Johansen KL; Lopes RD; Kler L; Macdougall IC; McMurray JJV; Meadowcroft AM; Obrador GT; Perkovic V; Solomon S; Wanner C; Waikar SS; Wheeler DC; Wiecek A
Nephrol Dial Transplant; 2022 Apr; 37(5):960-972. PubMed ID: 33744933
[TBL] [Abstract][Full Text] [Related]
10. Vadadustat in Patients with Anemia and Non-Dialysis-Dependent CKD.
Chertow GM; Pergola PE; Farag YMK; Agarwal R; Arnold S; Bako G; Block GA; Burke S; Castillo FP; Jardine AG; Khawaja Z; Koury MJ; Lewis EF; Lin T; Luo W; Maroni BJ; Matsushita K; McCullough PA; Parfrey PS; Roy-Chaudhury P; Sarnak MJ; Sharma A; Spinowitz B; Tseng C; Tumlin J; Vargo DL; Walters KA; Winkelmayer WC; Wittes J; Eckardt KU;
N Engl J Med; 2021 Apr; 384(17):1589-1600. PubMed ID: 33913637
[TBL] [Abstract][Full Text] [Related]
11. Molidustat for Renal Anemia in Nondialysis Patients Previously Treated with Erythropoiesis-Stimulating Agents: A Randomized, Open-Label, Phase 3 Study.
Yamamoto H; Nobori K; Matsuda Y; Hayashi Y; Hayasaki T; Akizawa T
Am J Nephrol; 2021; 52(10-11):884-893. PubMed ID: 34569482
[TBL] [Abstract][Full Text] [Related]
12. Daprodustat Compared with Epoetin Beta Pegol for Anemia in Japanese Patients Not on Dialysis: A 52-Week Randomized Open-Label Phase 3 Trial.
Nangaku M; Hamano T; Akizawa T; Tsubakihara Y; Nagai R; Okuda N; Kurata K; Nagakubo T; Jones NP; Endo Y; Cobitz AR
Am J Nephrol; 2021; 52(1):26-35. PubMed ID: 33561857
[TBL] [Abstract][Full Text] [Related]
13. The ASCEND-ND trial: study design and participant characteristics.
Perkovic V; Blackorby A; Cizman B; Carroll K; Cobitz AR; Davies R; DiMino TL; Jha V; Johansen KL; Lopes RD; Kler L; Macdougall IC; McMurray JJV; Meadowcroft AM; Obrador GT; Solomon S; Taft L; Wanner C; Waikar SS; Wheeler DC; Wiecek A; Singh AK
Nephrol Dial Transplant; 2022 Oct; 37(11):2157-2170. PubMed ID: 34865143
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of vadadustat compared with darbepoetin alfa in Japanese anemic patients on hemodialysis: a Phase 3, multicenter, randomized, double-blind study.
Nangaku M; Kondo K; Ueta K; Kokado Y; Kaneko G; Matsuda H; Kawaguchi Y; Komatsu Y
Nephrol Dial Transplant; 2021 Aug; 36(9):1731-1741. PubMed ID: 33650630
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Molidustat for Anemia in ESA-Naive Nondialysis Patients: A Randomized, Phase 3 Trial.
Yamamoto H; Nobori K; Matsuda Y; Hayashi Y; Hayasaki T; Akizawa T
Am J Nephrol; 2021; 52(10-11):871-883. PubMed ID: 34569489
[TBL] [Abstract][Full Text] [Related]
16. Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus > or = 10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial.
Vansteenkiste J; Hedenus M; Gascon P; Bokemeyer C; Ludwig H; Vermorken J; Hamilton L; Bridges K; Pujol B
BMC Cancer; 2009 Sep; 9():311. PubMed ID: 19728887
[TBL] [Abstract][Full Text] [Related]
17. Vadadustat for treatment of anemia in patients with dialysis-dependent chronic kidney disease receiving peritoneal dialysis.
Sarnak MJ; Agarwal R; Boudville N; Chowdhury PCP; Eckardt KU; Gonzalez CR; Kooienga LA; Koury MJ; Ntoso KA; Luo W; Parfrey PS; Vargo DL; Winkelmayer WC; Zhang Z; Chertow GM
Nephrol Dial Transplant; 2023 Sep; 38(10):2358-2367. PubMed ID: 37096396
[TBL] [Abstract][Full Text] [Related]
18. De novo weekly and biweekly darbepoetin alfa dosing in pediatric patients with chronic kidney disease.
Warady BA; Barcia J; Benador N; Jankauskiene A; Olson K; Podracka L; Shavkin A; Srivaths P; Wong CJ; Petersen J
Pediatr Nephrol; 2018 Jan; 33(1):125-137. PubMed ID: 28815341
[TBL] [Abstract][Full Text] [Related]
19. Darbepoetin Alfa in Patients with Advanced CKD without Diabetes: Randomized, Controlled Trial.
Hayashi T; Maruyama S; Nangaku M; Narita I; Hirakata H; Tanabe K; Morita S; Tsubakihara Y; Imai E; Akizawa T;
Clin J Am Soc Nephrol; 2020 May; 15(5):608-615. PubMed ID: 32245781
[TBL] [Abstract][Full Text] [Related]
20. A randomized, 29-day, dose-ranging, efficacy and safety study of daprodustat, administered three times weekly in patients with anemia on hemodialysis.
Bailey CK; Caltabiano S; Cobitz AR; Huang C; Mahar KM; Patel VV
BMC Nephrol; 2019 Oct; 20(1):372. PubMed ID: 31619187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
